Literature DB >> 15051890

Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis.

Eran R Andrechek1, William R Hardy, Michael A Laing, William J Muller.   

Abstract

We have previously shown that mammary epithelial specific expression of the activated erbB2 allele under the control of the endogenous promoter in mice resulted in the formation of mammary adenocarcinomas. To assess whether mammary tumorigenesis in this model is influenced by the developmental window of expression, we generated mice that expressed the activated erbB2 allele in the germ line. Although we were able to derive viable transgenic mice that were heterozygous for the activated erbB2 allele, mice homozygous for the activated erbB2 allele died at 12.5 days of embryogenesis. These two separate lines of mice expressed activated erbB2 at equal levels in the mammary gland. Surprisingly, unlike the tumor-prone mice expressing activated ErbB2 in the mammary epithelium, mice with the germ-line erbB2 allele failed to develop tumors. Gene expression analysis of the preneoplastic mammary glands revealed that there were a number of luminal epithelial markers expressed at higher levels in the tumor-prone mice. These data suggest either an expansion of a susceptible population in the tumor-prone mice or the loss of this population in the tumor-resistant mice. Taken together, these observations suggest that the temporal pattern of expression of activated ErbB2 is a critical determinant in mammary tumorigenesis. These results strongly suggest that there are feedback mechanisms present that can compensate for the expression of a potent oncogene.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051890      PMCID: PMC387360          DOI: 10.1073/pnas.0306802101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Skeletal disorders associated with fibroblast growth factor receptor mutations.

Authors:  L De Moerlooze; C Dickson
Journal:  Curr Opin Genet Dev       Date:  1997-06       Impact factor: 5.578

2.  Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles.

Authors:  W Xie; X Wu; L T Chow; E Chin; A J Paterson; J E Kudlow
Journal:  Cell Growth Differ       Date:  1998-04

3.  Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer.

Authors:  P M Siegel; E D Ryan; R D Cardiff; W J Muller
Journal:  EMBO J       Date:  1999-04-15       Impact factor: 11.598

4.  MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer.

Authors:  T K Bera; S Lee; G Salvatore; B Lee; I Pastan
Journal:  Mol Med       Date:  2001-08       Impact factor: 6.354

5.  Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice.

Authors:  W Xie; L T Chow; A J Paterson; E Chin; J E Kudlow
Journal:  Oncogene       Date:  1999-06-17       Impact factor: 9.867

Review 6.  Signal transduction in mammary tumorigenesis: a transgenic perspective.

Authors:  D L Dankort; W J Muller
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

7.  Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development.

Authors:  K Kiguchi; D Bol; S Carbajal; L Beltrán; S Moats; K Chan; J Jorcano; J DiGiovanni
Journal:  Oncogene       Date:  2000-08-31       Impact factor: 9.867

8.  Requirement for neuregulin receptor erbB2 in neural and cardiac development.

Authors:  K F Lee; H Simon; H Chen; B Bates; M C Hung; C Hauser
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

9.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.

Authors:  P M Siegel; W J Muller
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

10.  Activated neu induces rapid tumor progression.

Authors:  C T Guy; R D Cardiff; W J Muller
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

View more
  11 in total

Review 1.  Illuminating the center: mechanisms regulating lumen formation and maintenance in mammary morphogenesis.

Authors:  Mauricio J Reginato; Senthil K Muthuswamy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-10       Impact factor: 2.673

Review 2.  How to Choose a Mouse Model of Breast Cancer, a Genomic Perspective.

Authors:  Matthew R Swiatnicki; Eran R Andrechek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2019-06-21       Impact factor: 2.673

3.  Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.

Authors:  M D Landis; D D Seachrist; F W Abdul-Karim; R A Keri
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

4.  Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.

Authors:  Kanika Bajaj Pahuja; Thong T Nguyen; Bijay S Jaiswal; Kumar Prabhash; Tarjani M Thaker; Kate Senger; Subhra Chaudhuri; Noelyn M Kljavin; Aju Antony; Sameer Phalke; Prasanna Kumar; Marco Mravic; Eric W Stawiski; Derek Vargas; Steffen Durinck; Ravi Gupta; Arati Khanna-Gupta; Sally E Trabucco; Ethan S Sokol; Ryan J Hartmaier; Ashish Singh; Anuradha Chougule; Vaishakhi Trivedi; Amit Dutt; Vijay Patil; Amit Joshi; Vanita Noronha; James Ziai; Sripad D Banavali; Vedam Ramprasad; William F DeGrado; Raphael Bueno; Natalia Jura; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2018-10-25       Impact factor: 31.743

Review 5.  Stem/progenitor cells in mouse mammary gland development and breast cancer.

Authors:  Yi Li; Jeffrey M Rosen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-01       Impact factor: 2.673

6.  Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models.

Authors:  Zhijun Du; Katrina Podsypanina; Shixia Huang; Amanda McGrath; Michael J Toneff; Ekaterina Bogoslovskaia; Xiaomei Zhang; Ricardo C Moraes; Michele Fluck; D Craig Allred; Michael T Lewis; Harold E Varmus; Yi Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

7.  Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation.

Authors:  Jay P Reddy; Sirisha Peddibhotla; Wen Bu; Jing Zhao; Svasti Haricharan; Yi-Chieh Nancy Du; Katrina Podsypanina; Jeffrey M Rosen; Larry A Donehower; Yi Li
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-03       Impact factor: 11.205

Review 8.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

Review 9.  Transgenic models to study actions of prolactin in mammary neoplasia.

Authors:  Lisa M Arendt; Linda A Schuler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

10.  Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer.

Authors:  W Bu; J Chen; G D Morrison; S Huang; C J Creighton; J Huang; G C Chamness; S G Hilsenbeck; D R Roop; A D Leavitt; Y Li
Journal:  Oncogene       Date:  2011-05-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.